Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSant Uk.8fepf Regulatory News (SANB)

Share Price Information for Sant Uk.8fepf (SANB)

Share Price is delayed by 15 minutes
Get Live Data
142.00    0.00 (0.00%)
Bid:
139.00
Ask:
144.00
Spread: 5.00 (3.597%)
Market Cap: -
SANB Live PriceLast checked at - London Stock Exchange

Intraday Sant Uk.8fepf Share Chart

Publication of Final Terms

25 Mar 2025 09:36

RNS Number : 0606C
Santander UK Plc
25 March 2025
 

 

SANTANDER UK PLC

€30 BILLION EURO MEDIUM TERM NOTE PROGRAMME

PUBLICATION OF FINAL TERMS - SERIES B-1486

 

The following final terms (the Final Terms) are available for viewing:

 

Issue of EUR 750,000,000 Senior Floating Rate Notes due 2028 (ISIN XS3032031257) (Series B-1486) (the Notes) by Santander UK plc, under the €30 billion Euro Medium Term Note programme of Santander UK Group Holdings plc and Santander UK plc (the Programme).

 

To view the full Final Terms document, please click on or paste the following URL into the address bar of your browser:

 

http://www.rns-pdf.londonstockexchange.com/rns/0606C_1-2025-3-25.pdf

 

 

A copy of the Final Terms has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism. This website is not provided for, nor is it directed at, U.S. persons or persons in the United States. If you are a U.S. person, or you are viewing this page from the United States, you should exit this section of the website.

 

For further information, please contact:

 

Funding, Asset Rotation and Investor RelationsSantander UK plc2 Triton SquareRegent's PlaceLondon NW1 3AN

Email: mtf@santander.co.uk

 

DISCLAIMER - INTENDED ADDRESSEES

 

Please note that the information contained in the Final Terms and the Prospectus published in respect of the Programme on 5 April 2024, as supplemented on 30 April 2024, 24 July 2024, 9 August 2024, 20 November 2024, 5 February 2025 and 7 March 2025 (together, the Prospectus) may be addressed to and/or targeted at persons who are residents of particular countries only (as further specified in the Prospectus) and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms and the Prospectus is not addressed. Prior to relying on the information contained in the Final Terms and the Prospectus you must ascertain from the Final Terms and the Prospectus whether or not you are part of the intended addressees of the information contained therein.

 

Your right to access this service is conditional upon your compliance with the above requirement.

 

This publication of the Final Terms does not constitute an offer of securities for sale in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under any relevant securities laws of any state of the United States of America, and may not be offered or sold in the United States of America or to, or for the benefit of, U.S. persons (as defined in Regulation S of the Securities Act), unless the securities are registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFTPKPBNCBKKQNB
12
Date   Source Headline
5th Jun 20261:20 pmRNSPublication of a Supplementary Prospectus
5th Jun 20261:15 pmRNSPublication of a Supplementary Prospectus
29th May 20263:49 pmRNSAdmission to trading of Transferable Securities
18th May 20264:01 pmRNSNotice of Redemption
18th May 20263:23 pmRNSAdmission to trading of Transferable Securities
15th May 20262:49 pmRNSPublication of Final Terms
8th May 202610:58 amRNSPublication of a Supplementary Prospectus
1st May 20264:42 pmRNSPublication of a Supplementary Prospectus
1st May 20264:38 pmRNSPublication of a Supplementary Prospectus
1st May 20267:00 amRNSCash Acquisition of TSB Banking Group plc
29th Apr 20267:15 amRNSQuarterly Management Statement - Q1 2026
28th Apr 20264:01 pmRNSAdmission to Trading of Transferable Securities
1st Apr 20263:56 pmRNSPublication of a Prospectus
26th Mar 202611:12 amRNSAdmission to trading of Transferable Securities
25th Mar 20264:30 pmRNSPublication of Final Terms
17th Mar 202612:57 pmRNSPublication of a Prospectus
16th Mar 20264:43 pmRNSNotice of Redemption
10th Mar 20262:08 pmRNSPublication of a Supplementary Prospectus
10th Mar 20262:08 pmRNSPublication of a Supplementary Prospectus
10th Mar 20261:59 pmRNSPublication of a Supplementary Prospectus
10th Mar 20261:59 pmRNSPublication of a Supplementary Prospectus
10th Mar 20267:53 amRNSAnnual Financial Report
10th Mar 20267:53 amRNSAnnual Financial Report
26th Feb 202610:45 amRNSFinal Terms
17th Feb 202612:36 pmRNSPublication of Final Terms
4th Feb 20261:47 pmRNSPublication of a Supplementary Prospectus
4th Feb 20261:42 pmRNSPublication of a Supplementary Prospectus
4th Feb 20267:15 amRNSQuarterly Management Statement – Q4 2025
30th Jan 202610:31 amRNSSantander UK - Chief Executive Officer appointment
13th Jan 20264:29 pmRNSNotice of Redemption
29th Oct 20257:00 amRNSUpdate on Q3 2025 Results
3rd Oct 202511:00 amRNSSantander UK CEO to step down
3rd Oct 20257:00 amRNSSantander UK Board changes
29th Aug 20251:42 pmRNSPublication of Supplementary Prospectus
29th Aug 20251:33 pmRNSPublication of Supplementary Prospectus
29th Aug 20257:30 amRNSHalf-year Report 30 June 2025
30th Jul 20252:10 pmRNSPublication of Suppl.Prospcts
30th Jul 20252:04 pmRNSPublication of Suppl.Prospcts
30th Jul 20257:15 amRNSQuarterly Management Statement Q2 2025
21st May 20252:11 pmRNSPublication of Final Terms
16th May 20254:15 pmRNSChair Appointment
30th Apr 202512:43 pmRNSPublication of Supplementary Prospectus
30th Apr 202512:32 pmRNSPublication of Supplementary Prospectus
30th Apr 20257:15 amRNSQuarterly Management Statement – Q1 2025
4th Apr 20253:04 pmRNSPublication of a Prospectus
2nd Apr 20254:22 pmRNSNotice of Redemption
25th Mar 20259:40 amRNSPublication of Final Terms
25th Mar 20259:36 amRNSPublication of Final Terms
24th Mar 202512:55 pmRNSPublication of Final Terms
21st Mar 20255:16 pmRNSPublication of a Prospectus
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.